30 closest matches · ranked by relevance
Carcinoma, Large Cell · Neuroendocrine Tumors
Primary: Percentage of Participants Progression-free — 49.0 Percentage of participants
Lung Cancer
Primary: Number of Participants With a Response — 4 Participants — p=0.161
Non Small Cell Lung Cancer
Primary: 3-Year Overall Survival Rate — 45 percentage of participants
Small Cell Lung Cancer · Extensive Stage Lung Cancer · Chemonaive
Primary: Number of Participants Experiencing Dose Limiting Toxicity Regimen A - Phase I — 0; 1; 1 participants
Non-Small Cell Lung Cancer
Primary: Number of Participants Responding to the Vaccine — 6 Participants
Lung Cancer
Primary: Patient Response — 2; 1; 2; 27 participants
Non-small Cell Lung Cancer (NSCLC) · Stage IV NSCLC · Metastatic NSCLC
Primary: Objective Response Rate — 0; 1 participants
Lung Cancer
Primary: Toxic Death Rate — NA Participants
Limited Stage Small Cell Lung Cancer · Small Cell Lung Cancer
Primary: Progression-free Survival (PFS) — 14.5; 10.7 months
Small Cell Lung Cancer
Primary: Overall Survival — 8.1; 10.6 months — p=<0.01
Lung Cancer
Primary: 18 Month Survival — 58; 54 percentage of participants
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
Lung Cancer
Primary: Overall Response Rate — 65; 50 percentage of participants
Lung Cancer
Primary: Overall Survival (12-month Rate Reported) — 60.1; 50.8 percentage of participants — p=0.2103
Lung Cancer
Primary: Number of Grade 3/4 Toxicities Patients Experienced on Maintenance Bevacizumab Following Chemoradiation for Limited Stage - Small Cell Lung Cancer (LS-SCLC) — 2; 1; 1; 1…
Extensive Stage Lung Small Cell Carcinoma · Recurrent Lung Small Cell Carcinoma
Primary: Progression-free Survival (PFS) — 5.5; 4.9 months — p=0.17
Extensive-Stage Small Cell Lung Cancer
Primary: 1-year Survival — 38 percentage of participants
Lung Cancer
Primary: Overall Survival at 2 Years — 36.60 percentage of participants
Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 29; 50 percentage of participants
Lung Cancer
Primary: Number of Participants Showing Immunologic Response to Vaccine Within Six Months of Immunization — 22 participants with immunological response
Lung Cancer
Primary: Overall Response Rate Defined as Complete or Partial Response as Assessed by RECIST Version 1.0 Criteria. — 38.1; 0 percentage of patients
Non Small Cell Lung Cancer
Primary: Percentage of Subjects With Detectable Circulating T Cells After Treatment — 16.7 Percentage of participants
Lung Cancer
Primary: Maximum Tolerated Dose of Erlotinib Hydrochloride (Phase I) — 150 mg daily
Extensive Stage Small Cell Lung Cancer
Primary: Percentage of Participants Alive and Progression-free (PF) at 6 Months — 30.2 Percentage of Participants
Lung Cancer
Primary: Overall Survival at 12 Months — 57 percentage of participants
Bronchioloalveolar Cell Variant of Non-small Cell Lung Cancer
Primary: Overall Objective Response of OSI-774 — 1; 18; 31; 30 participants
Extensive Stage Small Cell Lung Cancer · Recurrent Small Cell Lung Cancer
Primary: Objective Response (Confirmed and Unconfirmed, Complete and Partial Responses Per RECIST) — 11; 2 percentage of participants
Carcinoma, Small Cell
Primary: Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 57 percentage of participants
Lung Cancer
Primary: Mediastinal Nodal Clearance Rate — 27 participants
Lung Cancer
Primary: Median Progression Free Survival — 7.8 Months